Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?
September 7th 2023Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.